214 related articles for article (PubMed ID: 35275285)
1. Endocrine therapy initiation among women with stage I-III invasive, hormone receptor-positive breast cancer from 2001-2016.
Bowles EJA; Ramin C; Buist DSM; Feigelson HS; Weinmann S; Veiga LHS; Bodelon C; Curtis RE; Vo JB; Berrington de Gonzalez A; Gierach GL
Breast Cancer Res Treat; 2022 May; 193(1):203-216. PubMed ID: 35275285
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen Initiation After Ductal Carcinoma In Situ.
Nichols HB; Bowles EJ; Islam J; Madziwa L; Stürmer T; Tran DT; Buist DS
Oncologist; 2016 Feb; 21(2):134-40. PubMed ID: 26768485
[TBL] [Abstract][Full Text] [Related]
3. Ethnic differences in initiation and timing of adjuvant endocrine therapy among older women with hormone receptor-positive breast cancer enrolled in Medicare Part D.
Farias AJ; Du XL
Med Oncol; 2016 Feb; 33(2):19. PubMed ID: 26786154
[TBL] [Abstract][Full Text] [Related]
4. Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK.
Bromley SE; Matthews A; Smeeth L; Stanway S; Bhaskaran K
J Cancer Surviv; 2019 Aug; 13(4):632-640. PubMed ID: 31321612
[TBL] [Abstract][Full Text] [Related]
5. Patterns of endocrine therapy in a national cohort of early stage HER2-positive breast cancer patients.
Tervonen HE; Daniels B; Tang M; Preen DB; Pearson SA
Pharmacoepidemiol Drug Saf; 2019 Jun; 28(6):812-820. PubMed ID: 30861596
[TBL] [Abstract][Full Text] [Related]
6. Women commencing anastrozole, letrozole or tamoxifen for early breast cancer: the impact of comorbidity and demographics on initial choice.
Kemp A; Preen DB; Saunders C; Boyle F; Bulsara M; Holman CD; Malacova E; Roughead EE
PLoS One; 2014; 9(1):e84835. PubMed ID: 24392158
[TBL] [Abstract][Full Text] [Related]
7. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson LJ; Dawson C; Lawrence DH; Bliss JM
Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
[TBL] [Abstract][Full Text] [Related]
8. Endocrine therapy initiation from 2001 to 2008 varies by age at breast cancer diagnosis and tumor size.
Bowles EJ; Buist DS; Chubak J; Yu O; Johnson J; Chestnut J; Boudreau DM
J Oncol Pract; 2012 Mar; 8(2):113-20. PubMed ID: 23077439
[TBL] [Abstract][Full Text] [Related]
9. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
Bui KT; Willson ML; Goel S; Beith J; Goodwin A
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
[TBL] [Abstract][Full Text] [Related]
10. Endocrine therapy use in the twenty-first century: usage rates and temporal trends illustrate opportunities for improvement for South Carolina Medicaid women.
Bedi JS; Mayo RM; Truong K; Chen L; Dickes L; Sherrill WW; Jones K
Breast Cancer Res Treat; 2018 Oct; 171(3):759-765. PubMed ID: 29971626
[TBL] [Abstract][Full Text] [Related]
11. Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting.
Gierach GL; Curtis RE; Pfeiffer RM; Mullooly M; Ntowe EA; Hoover RN; Nyante SJ; Feigelson HS; Glass AG; Berrington de Gonzalez A
JAMA Oncol; 2017 Feb; 3(2):186-193. PubMed ID: 27711920
[TBL] [Abstract][Full Text] [Related]
12. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study.
Le Ray I; Dell'Aniello S; Bonnetain F; Azoulay L; Suissa S
Breast Cancer Res Treat; 2012 Sep; 135(2):603-9. PubMed ID: 22903687
[TBL] [Abstract][Full Text] [Related]
13. Treatment adoption and relative effectiveness of aromatase inhibitors compared to tamoxifen in early breast cancer: A multi-institutional observational study.
Ferreira AR; Palha A; Correia L; Filipe P; Rodrigues V; Miranda A; André R; Fernandes J; Gouveia J; Passos-Coelho JL; Moreira A; Brito M; Ribeiro J; Metzger-Filho O; Lin NU; Costa L; Vaz-Luis I
Breast; 2018 Feb; 37():107-113. PubMed ID: 29131988
[TBL] [Abstract][Full Text] [Related]
14. Development of cardiometabolic risk factors following endocrine therapy in women with breast cancer.
Rillamas-Sun E; Kwan ML; Iribarren C; Cheng R; Neugebauer R; Rana JS; Nguyen-Huynh M; Shi Z; Laurent CA; Lee VS; Roh JM; Huang Y; Shen H; Hershman DL; Kushi LH; Greenlee H
Breast Cancer Res Treat; 2023 Aug; 201(1):117-126. PubMed ID: 37326764
[TBL] [Abstract][Full Text] [Related]
15. Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors.
Matthews AA; Peacock Hinton S; Stanway S; Lyon AR; Smeeth L; Lund JL; Bhaskaran K
Heart; 2021 Aug; 107(16):1327-1335. PubMed ID: 33177117
[TBL] [Abstract][Full Text] [Related]
16. Age-related differences in persistence in women with breast cancer treated with tamoxifen or aromatase inhibitors in Germany.
Jacob L; Hadji P; Kostev K
J Geriatr Oncol; 2016 May; 7(3):169-75. PubMed ID: 27091510
[TBL] [Abstract][Full Text] [Related]
17. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
[TBL] [Abstract][Full Text] [Related]
18. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
19. Trends in endocrine therapy prescription and survival in patients with non-metastatic hormone receptor positive breast cancer treated with endocrine therapy: A population based-study.
Mamguem Kamga A; Billa O; Ladoire S; Poillot ML; Jolimoy G; Roignot P; Coutant C; Desmoulins I; Maynadie M; Dabakuyo-Yonli TS
Breast; 2021 Oct; 59():79-86. PubMed ID: 34174766
[TBL] [Abstract][Full Text] [Related]
20. Adherence to Adjuvant Endocrine Therapy in Christchurch Women with Early Breast Cancer.
Robinson B; Dijkstra B; Davey V; Tomlinson S; Frampton C
Clin Oncol (R Coll Radiol); 2018 Jan; 30(1):e9-e15. PubMed ID: 29103853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]